Repligen Corporation

NasdaqGS RGEN

Repligen Corporation EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.04

Repligen Corporation EPS (Diluted) is USD -0.04 for the Trailing 12 Months (TTM) ending September 30, 2024, a -102.03% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Repligen Corporation EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 2.03, a -29.76% change year over year.
  • Repligen Corporation EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 2.89, a 37.62% change year over year.
  • Repligen Corporation EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 2.10, a 156.10% change year over year.
  • Repligen Corporation EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.82, a 67.35% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
Loading...
NasdaqGS: RGEN

Repligen Corporation

CEO Mr. Olivier Loeillot
IPO Date April 29, 1986
Location United States
Headquarters Building 1
Employees 1,783
Sector Health Care
Industries
Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Similar companies

HAE

Haemonetics Corporation

USD 79.96

0.69%

NVST

Envista Holdings Corp

USD 18.85

-0.74%

ATR

AptarGroup, Inc.

USD 154.61

0.47%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

TFX

Teleflex Incorporated

USD 179.17

0.35%

WST

West Pharmaceutical Services, Inc.

USD 328.96

-3.13%

BDX

Becton, Dickinson and Company

USD 235.80

-0.17%

RMD

ResMed Inc.

USD 228.83

-0.62%

MMSI

Merit Medical Systems, Inc.

USD 99.89

4.44%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

ISRG

Intuitive Surgical, Inc.

USD 538.88

-0.16%

StockViz Staff

January 15, 2025

Any question? Send us an email